Journal ArticleOPEN ACCESS

Enteroviral meningoencephalitis after anti-CD20 (Rituximab) treatment

Clinical infectious diseases: An official publication of the Infectious Diseases Society of America (2003) 36(3) e47-49
DOI: 10.1086/345746
98Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Treatment with the chimeric anti-CD20 monoclonal antibody rituximab induces rapid and long-lasting depletion of circulating B cells. We report the occurrence of enteroviral meningoencephalitis following rituximab therapy in 1 child with immune thrombocytopenia and in 1 adult patient with relapsed B cell lymphoma.

Cite

CITATION STYLE

APA

Quartier, P., Tournilhac, O., Archimbaud, C., Lazaro, L., Chaleteix, C., Millet, P., … Tardieu, M. (2003). Enteroviral meningoencephalitis after anti-CD20 (Rituximab) treatment. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 36(3), e47-49. https://doi.org/10.1086/345746

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free